Novo Nordisk's Wegovy with Semaglutide Reduces Heart Failure and COVID-19 Risks by Up to 29%

Aug 30, 2024, 09:14 AM

Novo Nordisk's Wegovy, containing semaglutide, has been shown to reduce the risk of severe complications in patients with a common form of heart failure, according to a new analysis. Research indicates that semaglutide, found in both Ozempic and Wegovy, can decrease the risk of heart failure events and cardiovascular death by up to 29%. A study involving 3,533 diabetic patients highlighted a 27% lower risk of heart-related complications. Additionally, a Harvard study suggests that these medications also reduce the risk of severe COVID-19 in individuals with obesity. The SELECT trial further supports these findings, showing reduced COVID-19-associated morbidity and mortality.